Previous 10 | Next 10 |
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Cyclerion Therapeutics Inc. (CYCN) is expected to report for Q1 2024
2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...
– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data ...
2023-06-01 16:40:27 ET Cyclerion Therapeutics ( NASDAQ: CYCN ) has received a formal notice from The Nasdaq stating that it has regained compliance with the $1/share minimum bid price requirement pursuant to Nasdaq Listing Rule. In order to regain compliance, the Co. was r...
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Cyclerion has regained compliance with...
2023-05-23 13:09:12 ET Gainers: CohBar ( CWBR ) +158% . Shuttle Pharmaceuticals ( SHPH ) +121% . Ocean Biomedical ( OCEA ) +108% . HeartCore Enterprises ( HTCR ) +110% . Lifecore Biomedical ( LFCR ) +66% . T Stamp ( IDAI ...
2023-05-15 13:49:08 ET Cyclerion Therapeutics ( NASDAQ: CYCN ) announced a reverse stock split of its outstanding common shares at a ratio of 1-for-20, effective as of 5:00 p.m. ET on May 15, 2023. The reverse stock split was approved by the Company’s stockholders at it...
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ...
News, Short Squeeze, Breakout and More Instantly...
Cyclerion Therapeutics Inc. Company Name:
CYCN Stock Symbol:
NYSE Market:
Cyclerion Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 1.8% to $131.88 on volume of 307,014,213 shares SRIVARU Holding Limited (SVMH) rose 49.2% to $0.2275 on volume of 274,465,266 shares Nauticus Robotics Inc. (KITT) rose 19.6% to $0.192 on volume of 161,46...
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is one of today's top gainers. The company's shares have moved 37.28% on the day to $2.81. Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serio...